Clinical Trial Update: REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients [Phase 2]

View source ↗

Summary

A Phase IIb trial evaluating NTx-265 (hCG and epoetin alfa) for acute ischemic stroke has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)
• Human chorionic gonadotropin (human chorionic gonadotropin)
• NTx-265

Snippet

Sponsor: Stem Cell Therapeutics Corp. | Conditions: Stroke | Phase 2 | Status: WITHDRAWN